MedTrace Logo

Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)

NCT02518672 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-10-04

No results posted yet for this study

Summary

Monoglyceride of DHA (DHA-MAG) is a lipid compound for which intestinal absorption would increase the ratio DHA / arachidonic acid (AA) and promote the synthesis of specific metabolites involved in the resolution of inflammation.

The PREMDIC project, initiated at the Centre Hospitalier Universitaire de Sherbrooke, is a randomized double-blind study for people with cystic fibrosis (CF) and aims to evaluate whether daily supplementation monoglyceride of DHA (a fatty acid omega-3 family) will reduce lung inflammation and improve pulmonary function.

Conditions

Interventions

DIETARY_SUPPLEMENT

MAG-DHA

MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.

DIETARY_SUPPLEMENT

Placebo

Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.

Sponsors & Collaborators

  • Centre de recherche du Centre hospitalier universitaire de Sherbrooke

    collaborator OTHER

  • Solutex GC S.L.

    collaborator INDUSTRY

  • SCF Pharma

    lead INDUSTRY

Principal Investigators

  • André M Cantin, M.D. · Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-03-31
Completion
2016-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518672 on ClinicalTrials.gov